In the treatment naïve lung adenocarcinoma samples, the multiplication of paclitaxel-metabolizing CYP2C8 and/or CYP3A4 was detected, and the CYP copy number increase was more prevalent in non-responder patients than in responders to paclitaxel therapy. Here, CYP3A4 is linked to lung adenocarcinoma.